Transcatheter Mitral Repair for Functional Mitral Regurgitation According to Left Ventricular Function: A Real-Life Propensity-Score Matched Study

Fecha de publicación: 01/06/2020 Fecha Ahead of Print: 09/06/2020

Autores de IIS La Fe

José Luis Díez Gil

Autor

Participantes ajenos a IIS La Fe

Pascual, I
Carrasco-Chinchilla, F
Benito-Gonzalez, T
Li, CH
Avanzas, P
Nombela-Franco, L
Pan, M
Frutos, AS
Freixa, X
Trillo-Nouche, R
Hernandez-Antolin, RA
Ikazuriaga, LA
Cruz-Gonzalez, I
Lopez-Minguez, JR
Berenguer-Jofresa, A
Sanchis, J
Ruiz-Quevedo, V
Urbano-Carrillo, C
Dominguez, JFO
Ortas-Nadal, MR
Navarro, EM
Carrillo, X
Alonso-Briales, JH
Fernandez-Vazquez, F
Serra, LA
Hernandez-Vaquero, D
Jimenez-Quevedo, P
Mesa, D
Rodriguez-Gabella, T
Regueiro, A
Monzonis, AM
Tahoces, LS
Gomez, LR
Trejo-Velasco, B
Becerra-Munoz, VM
Garrote-Coloma, C
Peregrina, EF
Lorca, R
De Agustin, JA
Romero, M
Amat-Santos, IJ
Sabate, M
Alvarez, ABC
Hernandez-Garcia, JM
Gualis, J
Arzamendi, D
Moris, C
Tirado-Conte, G
Sanchez-Recalde, A
Estevez-Loureiro, R

Grupos

Grupo de Investigación Clínica y Traslacional en Cardiología

Investigador Principal

Esther Roselló Lletí

Abstract

Background: Transcatheter mitral valve repair (TMVR) could improve survival in functional mitral regurgitation (FMR), but it is necessary to consider the influence of left ventricular ejection fraction (LVEF). Therefore, we compare the outcomes after TMVR with Mitraclip(R)between two groups according to LVEF. Methods: In an observational registry study, we compared the outcomes in patients with FMR who underwent TMVR with and without LVEF <30%. The primary endpoint was the combined one-year all-cause mortality and unplanned hospital readmissions due to HF. The secondary end-points were New York Heart Association (NYHA) functional class and mitral regurgitation (MR) severity. Propensity-score matching was used to create two groups with the same baseline characteristics, except for baseline LVEF. Results: Among 535 FMR eligible patients, 144 patients with LVEF <30% (group 1) and 144 with LVEF >30% (group 2) had similar propensity scores and were included in the analyses. The primary study endpoint was significantlly higher in group 1 (33.3% vs. 9.4%,p= 0.002). There was a maintained improvement in secondary endpoints without significant differences among groups. Conclusion: FMR patients with LVEF <30% treated with MitraClip(R)had higher mortality and readmissions than patients with LVEF >= 30% treated with the same device. However, both groups improved the NYHA functional class and MR severity.